PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 25445018-1 2015 A lectin secreted from Andrias davidianus skin (ADL) was purified by affinity chromatography on porcine stomach mucin (type III) (PSM)-crosslinked albumin, followed by gel filtration on Sephadex G-100 and HPLC on TSK gel G3000PWXL. sephadex 186-200 sarcoglycan alpha Homo sapiens 48-51 25445018-3 2015 SDS-PAGE showed that the ADL protein had a molecular mass of 17 kDa. Sodium Dodecyl Sulfate 0-3 sarcoglycan alpha Homo sapiens 25-28 25445018-4 2015 ADL produced an 8.5 kDa band when examined using SDS-PAGE under reducing conditions. Sodium Dodecyl Sulfate 49-52 sarcoglycan alpha Homo sapiens 0-3 23364036-5 2012 RESULTS: For men, ability to perform ADL & IADL (beta(32)=1.84, p<.001) accounted for 16% of the variance in the number of falls. Adenosine Monophosphate 42-45 sarcoglycan alpha Homo sapiens 37-40 25316116-6 2014 Conversely, only the Dag1 and Dag2 peptides exhibit some chain reversal; replacing the second aspartic-acid residue with a valine and the first one with a basic residue results in a nearly extended conformation. Aspartic Acid 94-107 sarcoglycan alpha Homo sapiens 30-34 25316116-6 2014 Conversely, only the Dag1 and Dag2 peptides exhibit some chain reversal; replacing the second aspartic-acid residue with a valine and the first one with a basic residue results in a nearly extended conformation. Valine 123-129 sarcoglycan alpha Homo sapiens 30-34 26133369-8 2015 AMPS is a useful measure of ADL ability but should be used in conjunction with measures of functional performance in order to plan interventions and supports for people with schizophrenia that reflect the complexity of factors affecting community functioning. Adenylyl sulfate 0-4 sarcoglycan alpha Homo sapiens 28-31 23364036-6 2012 For women, fear of falling (beta(31)=0.14, p<.05) and ability to perform ADL & IADL (beta(32)=1.01, p<.001) significantly contributed to the number of falls, accounting for 15% of the variance in the number of falls. Adenosine Monophosphate 81-84 sarcoglycan alpha Homo sapiens 76-79 18096255-8 2009 The water drinking and gargling function tests showed a strong correlation (p<0.001) with cognitive function and ADL. Water 4-9 sarcoglycan alpha Homo sapiens 116-119 20954215-1 2010 A rapid and reliable high-performance liquid chromatographic method for resolution of enantiomers of adrafinil [(+-)-ADL], a novel vigilance promoting agent, and its synthetic intermediates was developed. adrafinil 101-110 sarcoglycan alpha Homo sapiens 117-120 21122786-13 2010 This analysis of caregivers" requests for formal PCS brings to the forefront the role of ADL or functional status in this process. pcs 49-52 sarcoglycan alpha Homo sapiens 89-92 16365850-2 2006 The potential energy surfaces of the three different positional isomers of diaminoguanidine (DAG1, DAG2, and DAG3) have been studied in detail, which suggest greater stability for DAG1 over the other isomers. diaminoguanidine 75-91 sarcoglycan alpha Homo sapiens 99-103 15736300-2 2005 The most frequently reported mutation, 229CGC>TGC (R77C) in exon 3 of SGCA, results in the substitution of arginine by cysteine. Arginine 110-118 sarcoglycan alpha Homo sapiens 73-77 15736300-2 2005 The most frequently reported mutation, 229CGC>TGC (R77C) in exon 3 of SGCA, results in the substitution of arginine by cysteine. Cysteine 122-130 sarcoglycan alpha Homo sapiens 73-77 9585331-0 1998 Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Steroids 80-87 sarcoglycan alpha Homo sapiens 11-28 15537474-6 2004 On the ADL, donepezil- and galantamine-treated patients showed decreases of 0.44 and 0.86 points, respectively, while there was "no change" with rivastigmine. Donepezil 12-21 sarcoglycan alpha Homo sapiens 7-10 15537474-6 2004 On the ADL, donepezil- and galantamine-treated patients showed decreases of 0.44 and 0.86 points, respectively, while there was "no change" with rivastigmine. Galantamine 27-38 sarcoglycan alpha Homo sapiens 7-10 12876237-10 2003 In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). entacapone 54-64 sarcoglycan alpha Homo sapiens 27-30 12876237-13 2003 A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement. entacapone 98-108 sarcoglycan alpha Homo sapiens 163-166 12568834-12 2003 CONCLUSION(S): Overall efficacy of estrogen plus progesterone combination was similar to tacrine for cognition and mood, but greater for ADL. Progesterone 49-61 sarcoglycan alpha Homo sapiens 137-140 11290876-9 2001 At the end of 1-month follow-up, the Barthel ADL index was nonsignificantly higher and the Rankin disability score was marginally significantly lower in the magnesium-treated group (84 +/- 26 vs. 71.8 +/- 26, p < 0.143) than in control subjects (2.3 +/- 1.1 vs. 3 +/- 1.3, p < 0.077). Magnesium 157-166 sarcoglycan alpha Homo sapiens 45-48 10794752-7 2000 Plasma tHcy correlated with severity of dementia (r = 0.36; P <0.01), the Katz ADL index (r = 0.29; P <0.05), the Berger scale (r = 0.29; P <0.05), and the score of symptoms (r = 0.39; P <0.001) in the psychogeriatric population. thcy 7-11 sarcoglycan alpha Homo sapiens 82-85 10075685-6 1999 alpha-Sarcoglycan binds ATP in a Mg2+-dependent and Ca2+-independent manner. Adenosine Triphosphate 24-27 sarcoglycan alpha Homo sapiens 0-17 10075685-6 1999 alpha-Sarcoglycan binds ATP in a Mg2+-dependent and Ca2+-independent manner. magnesium ion 33-37 sarcoglycan alpha Homo sapiens 0-17 10075685-12 1999 These data suggest that alpha-sarcoglycan may modulate the activity of P2X receptors by buffering the extracellular ATP concentration. Adenosine Triphosphate 116-119 sarcoglycan alpha Homo sapiens 24-41 10075685-13 1999 The absence of alpha-sarcoglycan in sarcoglycanopathies leaves elevated the concentration of extracellular ATP and the persistent activation of P2X receptors, leading to intracellular Ca2+ overload and muscle fiber death. Adenosine Triphosphate 107-110 sarcoglycan alpha Homo sapiens 15-32 15032752-0 2004 Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan. Adenosine Triphosphate 24-27 sarcoglycan alpha Homo sapiens 52-69 15032752-3 2004 A first insight into the function of alpha-sarcoglycan was obtained by finding that it is an ATP-binding protein and that it probably confers ability to hydrolyse ATP to the purified dystrophin complex [Betto, Senter, Ceoldo, Tarricone, Biral and Salviati (1999) J. Biol. Adenosine Triphosphate 93-96 sarcoglycan alpha Homo sapiens 37-54 15032752-3 2004 A first insight into the function of alpha-sarcoglycan was obtained by finding that it is an ATP-binding protein and that it probably confers ability to hydrolyse ATP to the purified dystrophin complex [Betto, Senter, Ceoldo, Tarricone, Biral and Salviati (1999) J. Biol. Adenosine Triphosphate 163-166 sarcoglycan alpha Homo sapiens 37-54 15032752-6 2004 In the present study, we present definitive evidence showing that alpha-sarcoglycan is an ATP-hydrolysing enzyme. Adenosine Triphosphate 90-93 sarcoglycan alpha Homo sapiens 66-83 15032752-9 2004 25% of ecto-nucleotidase activity displayed by the C2C12 myotubes was inhibited by preincubating cells with an antibody specific for the ATP-binding motif of alpha-sarcoglycan. Adenosine Triphosphate 137-140 sarcoglycan alpha Homo sapiens 158-175 15032752-12 2004 Transfected cells exhibited a significant increase in the ATP-hydrolysing activity that was abolished by the anti-alpha-sarcoglycan antibody. Adenosine Triphosphate 58-61 sarcoglycan alpha Homo sapiens 114-131 15209643-1 2004 OBJECTIVES: To examine the effect of galantamine on activities of daily living (ADLs) with respect to baseline dementia severity, correlation with cognitive and global function, specific ADLs affected, and maintenance of ADL independence. Galantamine 37-48 sarcoglycan alpha Homo sapiens 80-83 15209643-7 2004 RESULTS: Galantamine resulted in more improvement in ADCS/ADL scores than placebo regardless of baseline dementia severity, with the greatest differences occurring in patients with more severe disease. Galantamine 9-20 sarcoglycan alpha Homo sapiens 58-61 15209643-9 2004 Galantamine treatment resulted in maintenance or improvement of basic and instrumental ADLs, and change from baseline to Month 5 in scores for each individual ADL item favored galantamine over placebo in three of six basic ADLs and six of 17 instrumental ADLs. Galantamine 0-11 sarcoglycan alpha Homo sapiens 87-90 15209643-10 2004 CONCLUSION: Galantamine has a favorable effect on ADL performance in patients with AD, detectable after 5 months of treatment, regardless of dementia severity. Galantamine 12-23 sarcoglycan alpha Homo sapiens 50-53 12212314-1 2002 PURPOSE: The purpose of this study was to investigate the relationship between ADL and residential environment for patients receiving home oxygen therapy. Oxygen 139-145 sarcoglycan alpha Homo sapiens 79-82 11271504-8 2000 A dystrophin-associated protein, alpha-sarcoglycan, has recently been shown to be an ecto-ATPase (an extracellular ATPase) capable of regulating ATP concentrations in the space between the cardiomyocytes. Adenosine Triphosphate 90-93 sarcoglycan alpha Homo sapiens 33-50 9455986-3 1997 The sequence of part of exon 3 of the alpha-sarcoglycan gene exhibited a cytosine to thymidine substitution at nucleotide position 220. Cytosine 73-81 sarcoglycan alpha Homo sapiens 38-55 9646269-6 1998 The molecular study evidenced an homozygous point mutation (Arg-->Cys) at position 77 of exon 3 of the gene coding for the 50 kD subunit of the alpha-sarcoglycan complex localised in chromosome 17. Arginine 60-63 sarcoglycan alpha Homo sapiens 147-164 9646269-6 1998 The molecular study evidenced an homozygous point mutation (Arg-->Cys) at position 77 of exon 3 of the gene coding for the 50 kD subunit of the alpha-sarcoglycan complex localised in chromosome 17. Cysteine 69-72 sarcoglycan alpha Homo sapiens 147-164 9455986-3 1997 The sequence of part of exon 3 of the alpha-sarcoglycan gene exhibited a cytosine to thymidine substitution at nucleotide position 220. Thymidine 85-94 sarcoglycan alpha Homo sapiens 38-55 8615174-3 1996 There was 50% relief in disability scores and ADL in 13 patients in the first group in the combined therapy for 12 weeks with lisuride added to L-DOPA plus benserazide (p < 0.01). Lisuride 126-134 sarcoglycan alpha Homo sapiens 46-49 9120997-8 1997 Half of the families have the cytosine to thymidine substitution at nt.229, resulting in the replacement of Arg by Cys at codon 77, and most of the mutations have been found in the region coding extracellular domain of alpha-sarcoglycan. Cytosine 30-38 sarcoglycan alpha Homo sapiens 219-236 9120997-8 1997 Half of the families have the cytosine to thymidine substitution at nt.229, resulting in the replacement of Arg by Cys at codon 77, and most of the mutations have been found in the region coding extracellular domain of alpha-sarcoglycan. Thymidine 42-51 sarcoglycan alpha Homo sapiens 219-236 8615174-6 1996 Monotherapy with lisuride resulted in 56% to 57% improvement in disability scores and 47% in relief in ADL. Lisuride 17-25 sarcoglycan alpha Homo sapiens 103-106 7581448-4 1995 A Thr-to-Arg missense mutation was identified within the beta-sarcoglycan gene that leads to a dramatically reduced expression of beta-sarcoglycan in the sarcolemma and a concomitant loss of adhalin and 35 DAG, which may represent a disruption of a functional subcomplex within the dystrophin-glycoprotein complex. Threonine 2-5 sarcoglycan alpha Homo sapiens 191-198 8825019-3 1996 Beta-dystroglycan of 43 kDa, together with the 50 kDa protein adhalin and three other dystrophin-associated glycoproteins of 25, 35 and 43 kDa form this sarcolemmal complex which binds to the cysteine-rich domain of dystrophin. Cysteine 192-200 sarcoglycan alpha Homo sapiens 62-69 7581448-4 1995 A Thr-to-Arg missense mutation was identified within the beta-sarcoglycan gene that leads to a dramatically reduced expression of beta-sarcoglycan in the sarcolemma and a concomitant loss of adhalin and 35 DAG, which may represent a disruption of a functional subcomplex within the dystrophin-glycoprotein complex. Arginine 9-12 sarcoglycan alpha Homo sapiens 191-198 34909730-4 2021 The amounts of C24 and C26 free fatty acids and C24 and C26 ceramides-oxidized exclusively in peroxisomes-were reduced in the epidermis of ft/ft mice despite increased lipid synthesis, similar to that seen in human ADL edpidermis. Fatty Acids 32-43 sarcoglycan alpha Homo sapiens 215-218 7481173-7 1995 RESULTS: Both groups deteriorated, but the decline was significantly slower in the GL-group regarding some ADL-functions, e.g. dressing and motor functions, whereas some behavioural disturbances were significantly more frequent in the GL-group. glycylleucine 83-85 sarcoglycan alpha Homo sapiens 107-110 34925204-11 2021 Conclusion: Combined with HBOT, tDCS can help improve cognitive function and ADL in patients with DEACMP. deacmp 98-104 sarcoglycan alpha Homo sapiens 77-80 7657792-3 1995 Sequencing of adhalin cDNA prepared from skeletal muscle by reverse transcription PCR demonstrated a cytosine to thymidine substitution at nt 229 in the patient in family 1 and an adenine to guanine substitution at nt 410 and a 15-base insertion between nt 408 and 409 in the two patients in family 2. Cytosine 101-109 sarcoglycan alpha Homo sapiens 14-21 7657792-3 1995 Sequencing of adhalin cDNA prepared from skeletal muscle by reverse transcription PCR demonstrated a cytosine to thymidine substitution at nt 229 in the patient in family 1 and an adenine to guanine substitution at nt 410 and a 15-base insertion between nt 408 and 409 in the two patients in family 2. Thymidine 113-122 sarcoglycan alpha Homo sapiens 14-21 7657792-3 1995 Sequencing of adhalin cDNA prepared from skeletal muscle by reverse transcription PCR demonstrated a cytosine to thymidine substitution at nt 229 in the patient in family 1 and an adenine to guanine substitution at nt 410 and a 15-base insertion between nt 408 and 409 in the two patients in family 2. Adenine 180-187 sarcoglycan alpha Homo sapiens 14-21 7657792-3 1995 Sequencing of adhalin cDNA prepared from skeletal muscle by reverse transcription PCR demonstrated a cytosine to thymidine substitution at nt 229 in the patient in family 1 and an adenine to guanine substitution at nt 410 and a 15-base insertion between nt 408 and 409 in the two patients in family 2. Guanine 191-198 sarcoglycan alpha Homo sapiens 14-21 34909730-4 2021 The amounts of C24 and C26 free fatty acids and C24 and C26 ceramides-oxidized exclusively in peroxisomes-were reduced in the epidermis of ft/ft mice despite increased lipid synthesis, similar to that seen in human ADL edpidermis. Ceramides 60-69 sarcoglycan alpha Homo sapiens 215-218 32358060-2 2020 Although heme must bind in the sGC beta1 subunit (sGCbeta) for sGC to function, how heme is delivered to sGCbeta remains unknown. Heme 9-13 sarcoglycan alpha Homo sapiens 50-57 35089807-1 2022 Nitric oxide (NO) binds soluble guanylyl cyclase beta (sGCbeta) to produce cGMP and relax vascular smooth muscle cells (SMC) needed for vasodilation. Nitric Oxide 0-12 sarcoglycan alpha Homo sapiens 55-62 35089807-1 2022 Nitric oxide (NO) binds soluble guanylyl cyclase beta (sGCbeta) to produce cGMP and relax vascular smooth muscle cells (SMC) needed for vasodilation. Cyclic GMP 75-79 sarcoglycan alpha Homo sapiens 55-62 3722977-5 1986 Mean period from the start of steroid therapy to manifestation of lesion was 79 months and mean total dose was 29.0 g. Subjectively, knee pain was not so severe and ADL was not so limited in most cases. Steroids 30-37 sarcoglycan alpha Homo sapiens 165-168 33848270-7 2021 Using adenine base editing, we corrected the mutation in the cells from both donors with >90% efficiency, thereby rescuing the splicing defect and alpha-sarcoglycan expression. Adenine 6-13 sarcoglycan alpha Homo sapiens 147-164 33975383-4 2022 Heme content of sGCbeta was monitored in live cells through use of a fluorescent-labeled sGCbeta construct, while sGC heterodimer status and protein interactions were studied by Western analysis. Heme 0-4 sarcoglycan alpha Homo sapiens 16-23 33975383-8 2022 Treating a purified ferrous heme-containing sGCbeta with ODQ or NOC12 caused it to bind with Hsp90 without showing any heme loss. ferrous heme 20-32 sarcoglycan alpha Homo sapiens 44-51 33975383-8 2022 Treating a purified ferrous heme-containing sGCbeta with ODQ or NOC12 caused it to bind with Hsp90 without showing any heme loss. 1H-(1,2,3)oxadiazolo(4,4-a)quinoxalin-1-one 57-60 sarcoglycan alpha Homo sapiens 44-51 33975383-8 2022 Treating a purified ferrous heme-containing sGCbeta with ODQ or NOC12 caused it to bind with Hsp90 without showing any heme loss. Heme 28-32 sarcoglycan alpha Homo sapiens 44-51 33393442-7 2021 The results showed that self-efficacy partially mediated the association between ADL, IADL, depression, and capacity of self-care on ESN. ERK1/2 inhibitor 1 133-136 sarcoglycan alpha Homo sapiens 81-84 34177288-7 2021 In all subjects and in the diabetic group, there was a negative correlation between CCI and Katz ADL (r = -0.343, P = .001; r = -0.383, P = .001, respectively); there was a positive correlation between CCI and number of drugs (r = 0.430, P = .001; r = 0.248, P = .001, respectively). CCI 84-87 sarcoglycan alpha Homo sapiens 97-100 33975383-9 2022 CONCLUSION AND IMPLICATIONS: Oxidative (ODQ) or nitrosative (NOC12) inactivation of cell sGC involves sGC heterodimer dissociation and rearrangement of the sGCbeta protein partners without any heme loss from sGCbeta. Heme 193-197 sarcoglycan alpha Homo sapiens 156-163 32330433-10 2021 Prednisolone increased the global ADL score in children younger than 5 years of age who had developmental regression (p=0.0057). Prednisolone 0-12 sarcoglycan alpha Homo sapiens 34-37 32802307-9 2020 The PD patients" L-dopa equivalent dose seems to be a strong predictor of the ADL-level in the morning. Levodopa 17-23 sarcoglycan alpha Homo sapiens 78-81 32358060-6 2020 We found that heme delivery to apo-sGCbeta correlates with cellular GAPDH expression levels and depends on the ability of GAPDH to bind intracellular heme, that apo-sGCbeta associates with GAPDH in cells and dissociates when heme binds sGCbeta, and that the purified GAPDH-heme complex binds to apo-sGCbeta and transfers its heme to sGCbeta. Heme 150-154 sarcoglycan alpha Homo sapiens 35-42 32358060-6 2020 We found that heme delivery to apo-sGCbeta correlates with cellular GAPDH expression levels and depends on the ability of GAPDH to bind intracellular heme, that apo-sGCbeta associates with GAPDH in cells and dissociates when heme binds sGCbeta, and that the purified GAPDH-heme complex binds to apo-sGCbeta and transfers its heme to sGCbeta. Heme 150-154 sarcoglycan alpha Homo sapiens 35-42 32358060-6 2020 We found that heme delivery to apo-sGCbeta correlates with cellular GAPDH expression levels and depends on the ability of GAPDH to bind intracellular heme, that apo-sGCbeta associates with GAPDH in cells and dissociates when heme binds sGCbeta, and that the purified GAPDH-heme complex binds to apo-sGCbeta and transfers its heme to sGCbeta. Heme 150-154 sarcoglycan alpha Homo sapiens 35-42 32358060-6 2020 We found that heme delivery to apo-sGCbeta correlates with cellular GAPDH expression levels and depends on the ability of GAPDH to bind intracellular heme, that apo-sGCbeta associates with GAPDH in cells and dissociates when heme binds sGCbeta, and that the purified GAPDH-heme complex binds to apo-sGCbeta and transfers its heme to sGCbeta. Heme 150-154 sarcoglycan alpha Homo sapiens 35-42 32358060-7 2020 On the basis of these results, we propose a model where GAPDH obtains mitochondrial heme and then forms a complex with apo-sGCbeta to accomplish heme delivery to sGCbeta. Heme 84-88 sarcoglycan alpha Homo sapiens 123-130 32358060-7 2020 On the basis of these results, we propose a model where GAPDH obtains mitochondrial heme and then forms a complex with apo-sGCbeta to accomplish heme delivery to sGCbeta. Heme 145-149 sarcoglycan alpha Homo sapiens 123-130 32358060-7 2020 On the basis of these results, we propose a model where GAPDH obtains mitochondrial heme and then forms a complex with apo-sGCbeta to accomplish heme delivery to sGCbeta. Heme 145-149 sarcoglycan alpha Homo sapiens 162-169 32358060-4 2020 We utilized an sGCbeta reporter construct, tetra-Cys sGCbeta, whose heme insertion can be followed by fluorescence quenching in live cells, assessed how lowering cell GAPDH expression impacts heme delivery, and examined whether expressing WT GAPDH or a GAPDH variant defective in heme binding recovers heme delivery. Cysteine 49-52 sarcoglycan alpha Homo sapiens 15-22 32358060-4 2020 We utilized an sGCbeta reporter construct, tetra-Cys sGCbeta, whose heme insertion can be followed by fluorescence quenching in live cells, assessed how lowering cell GAPDH expression impacts heme delivery, and examined whether expressing WT GAPDH or a GAPDH variant defective in heme binding recovers heme delivery. Heme 68-72 sarcoglycan alpha Homo sapiens 15-22 32358060-5 2020 We also studied interaction between GAPDH and sGCbeta in cells and their complex formation and potential heme transfer using purified proteins. Heme 105-109 sarcoglycan alpha Homo sapiens 46-53 32358060-6 2020 We found that heme delivery to apo-sGCbeta correlates with cellular GAPDH expression levels and depends on the ability of GAPDH to bind intracellular heme, that apo-sGCbeta associates with GAPDH in cells and dissociates when heme binds sGCbeta, and that the purified GAPDH-heme complex binds to apo-sGCbeta and transfers its heme to sGCbeta. Heme 14-18 sarcoglycan alpha Homo sapiens 35-42 32196634-7 2020 In a model that also included all six ADLs, loss of independence in each ADL was associated with declines in MCS, with the largest effects for eating and bathing. mcs 109-112 sarcoglycan alpha Homo sapiens 38-41 32196634-8 2020 MCS decreased by 1.3 per each additional summative loss of ADL independence (P < .001). mcs 0-3 sarcoglycan alpha Homo sapiens 59-62 31311859-3 2019 Heme insertion into the beta1 subunit of sGC (sGCbeta) is critical for function, and heat shock protein 90 (HSP90) associates with heme-free sGCbeta (apo-sGCbeta) to drive its heme insertion. Heme 0-4 sarcoglycan alpha Homo sapiens 46-53 31836381-4 2020 Next generation sequencing (NGS) revealed a known homozygous c.850C > T (p.Arg284Cys) mutation in SGCA gene. arg284cys 75-84 sarcoglycan alpha Homo sapiens 98-102 30988014-4 2019 Here, we demonstrate that pharmacological inhibition of Forkhead box subclass O (FoxO) transcription factors using the small-molecule inhibitor AS1842856 significantly blunts sGC alpha and beta mRNA expression by more than 90%. 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 144-153 sarcoglycan alpha Homo sapiens 175-184 31311859-3 2019 Heme insertion into the beta1 subunit of sGC (sGCbeta) is critical for function, and heat shock protein 90 (HSP90) associates with heme-free sGCbeta (apo-sGCbeta) to drive its heme insertion. Heme 131-135 sarcoglycan alpha Homo sapiens 141-148 31311859-3 2019 Heme insertion into the beta1 subunit of sGC (sGCbeta) is critical for function, and heat shock protein 90 (HSP90) associates with heme-free sGCbeta (apo-sGCbeta) to drive its heme insertion. Heme 131-135 sarcoglycan alpha Homo sapiens 141-148 31311859-3 2019 Heme insertion into the beta1 subunit of sGC (sGCbeta) is critical for function, and heat shock protein 90 (HSP90) associates with heme-free sGCbeta (apo-sGCbeta) to drive its heme insertion. Heme 176-180 sarcoglycan alpha Homo sapiens 46-53 31311859-3 2019 Heme insertion into the beta1 subunit of sGC (sGCbeta) is critical for function, and heat shock protein 90 (HSP90) associates with heme-free sGCbeta (apo-sGCbeta) to drive its heme insertion. Heme 176-180 sarcoglycan alpha Homo sapiens 141-148 31311859-3 2019 Heme insertion into the beta1 subunit of sGC (sGCbeta) is critical for function, and heat shock protein 90 (HSP90) associates with heme-free sGCbeta (apo-sGCbeta) to drive its heme insertion. Heme 176-180 sarcoglycan alpha Homo sapiens 141-148 31311859-6 2019 Our findings uncover the molecular features of the cellular apo-sGCbeta-HSP90 complex and reveal its dual importance in enabling heme insertion while preventing inactive heterodimer formation during sGC maturation. Heme 129-133 sarcoglycan alpha Homo sapiens 64-71 28086917-1 2017 BACKGROUND: Treatment of mild-moderate Alzheimer"s disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Abeta40 levels and activities of daily living (ADL) scores. Resveratrol 121-132 sarcoglycan alpha Homo sapiens 252-255 28086917-6 2017 In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Abeta42 levels during the 52-week trial, but did not alter tau levels. Resveratrol 25-36 sarcoglycan alpha Homo sapiens 126-129 28086917-6 2017 In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Abeta42 levels during the 52-week trial, but did not alter tau levels. Resveratrol 25-36 sarcoglycan alpha Homo sapiens 131-139 27974213-6 2016 In conclusion, a transcriptional blockade of mitochondrial biogenesis occurred in LGMD-2D and could be recovered by TSA changing chromatin conformation, or it could be overcome by NO activating a mitochondrial salvage pathway. trichostatin A 116-119 sarcoglycan alpha Homo sapiens 82-89 27108605-9 2016 We also observed a statistically significant improvement in global QoL and in the subscales mobility, ADL, stigma and bodily discomfort in patients after 3 months of rasagiline therapy. rasagiline 166-176 sarcoglycan alpha Homo sapiens 102-105